Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Eon Systems demonstrated the first embodied whole-brain emulation of a fruit fly — 139,255 neurons running in a physics-simulated body. The achievement bridges connectomics and AI, but the gap to a human brain remains enormous.
$75 million. Oversubscribed. For a platform most biotech investors haven't heard of — yet. Lycia Therapeutics, a South San Francisco biotech built on Nobel Prize-winning chemistry, closed its Series D on June 25. The round was co-led by Janus Henderson and Balyasny Asset Management, with participation from
London biotech RQ Bio raised $115M for RQB01, a long-acting antibody aiming to replace annual flu shots for high-risk patients.
The global clinical pipeline contains over 22,000 active compounds. Yet 90% of candidates fail. AI, regulatory reform, and new modalities are reshaping how drugs go from target discovery to commercial launch.
The WEF's 3C framework — combination, convergence, compounding — explains why the winners in tech are no longer the most advanced, but the most ready to integrate.
NewLimit raised $435M at $3.1B valuation for the first human trial of epigenetic reprogramming. A chronicle of the company's journey from seed to clinic.
Drug discovery timelines are compressing from a decade to eighteen months. A guide to the AI platforms and gene editing technologies rewriting the rules of pharmaceutical R&D.
The WEF's Top 10 Emerging Technologies report reveals a shift toward distributed systems — but every decentralized node creates a new central control point. A debate.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
